Profitability
Weight: 15%
F
0
- 5yr Avg ROIC -19.2%
- Operating Margin Trend -50374.54 pp/yr
FDMT
4D Molecular Therapeutics, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 29.8 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -23.0%
- 5yr Share-Count CAGR 20.2%
Growth Quality
Weight: 35%
B-
64
- 5yr Revenue CAGR 47.4%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -75611.1%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
D+
41
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 2.14
Stability
Weight: 5%
B-
67
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 2
- Negative-Revenue Years (5) 2/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 2 gurus held; 1 trimmed; 1 full exit.
- Holders
- 1 -1
- Avg Δ position
- -78.5%
- New buys
- 0
- Full exits
- 1